ACA
GPCR icon

Avoro Capital Advisors’s Structure Therapeutics GPCR Stock Holding History

Avoro Capital Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352M Hold
6,555,555
– – 3.16% 11
2026
Q1 		$316M Hold
6,555,555
– – 3.11% 12
2025
Q4 		$456M Buy
6,555,555
+1,400,000
+27% +$57.2M 4.48% 8
2025
Q3 		$144M Buy
+5,155,555
New +$103M 1.87% 17
2024
Q1 		– Sell
-2,333,333
Closed -$95.1M – 48
2023
Q4 		$95.1M Buy
2,333,333
+1,333,333
+133% +$76.4M 1.31% 19
2023
Q3 		$50.4M Buy
+1,000,000
New +$32.2M 0.79% 21

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Avoro Capital Advisors's GPCR Position: Q2 2026 in Review

Avoro Capital Advisors held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 6,555,555 shares worth $352M. The position accounts for 3.16% of the portfolio, ranked #11.

Avoro Capital Advisors first reported a position in GPCR in Q3 2023 and has held it in 6 quarters since. The position peaked at $456M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Avoro Capital Advisors held 6,555,555 shares of Structure Therapeutics worth $352M as of Q2 2026.
  • Avoro Capital Advisors left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up 3.16% of Avoro Capital Advisors's portfolio in Q2 2026, its #11 holding.
  • Avoro Capital Advisors first reported a position in Structure Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • Avoro Capital Advisors's Structure Therapeutics position peaked at $456M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.